AbbVie (ABBV) and Genmab (GMAB) announced that their jointly developed bispecific antibody epcoritamab, marketed as Epkinly ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Deep Origin docking software and molecular dynamics simulations pinpointed the lead compound from a 17-compound libraryComputational results ...
Company Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement ...
A drug co-developed by Genmab and AbbVie to treat a certain type of lymphoma failed to meet its primary endpoint in a Phase 3 trial. The companies on Thursday clarified that the trial's sole U.S.
Clinical characteristics and independent prognostic factors of patients with mantle cell lymphoma over last two decades with a focus on the interaction between tumor stage and age. This is an ASCO ...
Suchitra Sundaram, MD, emphasizes the significant disparities in the treatment and outcomes of patients with diffuse large B-cell lymphoma (DLBCL), which arise from a complex interaction of factors ...
Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography? The following represents disclosure information provided by the author of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results